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ABSTRACT 
Non- alcoholic fatty liver disease (NAFLD) is also otherwise termed as Hepatic steatosis and 
Kaphaja yakrit dalludara in Ayurveda. 34 years male patient, highly educated from a high socio-
economic group of Non vegetarian diet habit came to hospital with complain of anorexia, 
indigestion and distention for three months. The clinical findings revealed that he is slightly obese, 
hyperglycaemia and dyslipidimia along elevated liver enzymes with fatty liver in USG and Fibro 
scan. The case was treated with Patolakaturohinyadi Kwatham (PKK) in the dose was 30ml Kasaya 
with equal quantity of luke warm water twice daily in empty stomach preferable morning and 
evening for six months. This study proved that PKK can significantly reduced blood sugar, serum 
Lipids and liver enzymes within three months along with reduction weight and BMI, but change in 
liver architecture required six months in this therapy. The BARD score and NAFLD score changed to 
normal after six months of therapy. The patient was kept in observation for further one year 
without medication and advised to practice Yoga, exercise and low carbohydrate and fat diet to 
study the recurrence of disease. The liver architecture as well as biochemical profile of liver is 
maintained after one year also. PKK may correct the metabolic dysfunction by increase Agni, digest 
Ama which helped in the correction of hyperglycaemia and dyslipidaemia. PKK is safe in for six 
months of use in recommended dose (30ml BID) as there was no adverse sign and symptom 
observed and no change in biochemical and Haematological profile of Patients.PKK is safe and 
effective in this case of Kaphaja Yakrit dalludara (NAFLD). It can study further in large population 
to generated evidence for its efficacy and efficacy in larger group. 
KEYWORDS: Kaphaja yakrit dalludara, Non-alcoholic fatty liver disease (NAFLD), Patolakaturohinyadi 
Kwatham (PKK). 
INTRODUCTION 
 Yakrit dalludara is broad term in Ayurveda 
where the increase in size of Liver (Yakrit vridhi). 
When there is an increase of Kapha dosa leads to 
increase in size of Liver, then Kaphaja Yakrit 
dalludara takes place. Then it increase the Meda 
inside the Yakrit leads to Medaja Yakritdalludara[1]. 
Non-alcoholic fatty liver disease (NAFLD) is also 
otherwise termed as Hepatic steatosis and Kaphaja 
yakrit dalludara in Ayurveda, fat deposition in liver 
absence of excessive alcohol intake[2]. It is a global 
public health due to dietary hyper nutrition 
subsequent obesity, type-II diabetics and associated 
with smoking, hypertension and dyslipidaemia. 
NAFLD is an umbrella term used to described 
a histological spectrum ranging from simple 
steatosis, a concentration of hepatic triglycerides 
(TGs) exceeding 5% of liver weight, to non-alcoholic 
steatohepatitis (NASH) characterized by 
hepatocellular damage, lobular necroinflammation, 
fibrogenesis resulting cirrhosis, and cancer[3]. The 
prevalence of NAFLD is 15-40% in Western countries 
and 9-40% in Asia. Recent studies from the Indian 
subcontinent recorded a NAFLD prevalence of 9–
32% in the general population4. Metabolic 
perturbations, including insulin resistance, impaired 
glycaemic control, and altered lipid metabolism, have 
been hypothesized to contribute to the molecular 
pathogenesis of NAFLD and NASH5. Various 
pharmacological and non-pharmacological 
approaches seem to be non-effective and the patients 
are kept on long term treatment. Hence, even the 
highly educated patients reach to various traditional 
and alternative practitioners with an expectation of 
positive outcome[6]. Moreover, currently used 
medical treatment has been shown to be severe side 
effect and some have been associated with increased 
risk of certain type of cancer. Recent Randomised 
Clinical Trial demonstrated that phyto-medicine 
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reduces steosis severity, liver ballooning and fibrosis 
and can be comparable with western medical 
system[7,8]. Ayurveda medication in NAFLD is in 
conclusive[9,10] and limited to case studies[11] and 
literature review[12]. Although more than ten clinical 
trials of Ayurveda formulations are registered for 
NAFLD, yet more evidences required for the efficacy 
and safety of Ayurveda formulation in Non-alcoholic 
fatty liver diseases. Many patients demand for one 
poly herbal formulation which will be economic, no 
side effect and easy to take. Moreover, Potala 
katurohinyadi Kwatham is a known medicine for 
anorexia, vomiting, skin diseases, jaundice, viral 
infections and liver diseases phyto- chemical analysis 
is studied.[13,14]. Therefore, this case study is unique to 
study the safety and efficacy of Potala katurohinyadi 
Kwatham in Non-alcoholic fatty liver diseases 
primarily. 
Patient Information 
A 34 years male patient, highly educated from 
a high socio-economic group of Non vegetarian diet 
habit came to hospital July 2018 with complain of 
anorexia, indigestion and distention for three 
months. He is a lawyer in profession and his father 
has been suffering from diabetic and dyslipidaemia. 
The patient gave the history of weight gain of 6kg 
within one year. No history of intravenous drug use, 
blood transfusion and unsafe sex practice.  
The patient has taken modern appetizer, 
antacid and rapeprazole sodium for one month, but 
not satisfying with the relief. Therefore, he came for 
Ayurveda medication. 
 
 
 
Clinical Findings 
The case was having central obesity having 75kg 
weight and 163cm height (BMI-28.2). His viral 
hepatis screening was negative antinuclear antibody, 
smooth muscle antibody, α1-antitrypsin, 
ceruloplasmin, and thyroid-stimulating hormone 
levels were within normal limit. His fasting blood 
sugar is 122mg/dl, PPBS was 162mg/dl, HbA1c was 
7.1 and fasting insulin was 30mlU/L. His serum total 
bilirubin was 1.0mg/dl with direct was 0.3mg/dl, 
SGOT was 54 U/L, SGPT was 45 U/L, alkaline 
phosphate 138u/l, GGT (Gamma-glutamyl 
transferase) was 64U/L (Normal range 03-60U/L), 
serum urea- 26.0mg/dl (normal range 13-45mg/dl), 
serum creatinine 0.62 (normal range 0.6-1.2mg/dl), 
total protein 6.2 and serum albumin was 4.2mg/dl, 
Serum cholesterol was 137mg/dl, TG was 227mg/dl, 
HDL was 38mg/dl, Haemoglobin was 12.8gm/dl, 
total thrombocyte (PLT) was 148x109//L, TLC-
8700cells/cumm and ESR 1st hour was 06mm. He has 
elevated echo genicity and mild hepatomegaly in 
sonography report and mid line shift was 12 in liver 
electrography (Fibro scan).  
The patient’s Dosha vidha Prikshya (Tenfold 
of comprehensive bio-psycho-spiritual clinical 
review) as Kapha Pitta prakruti, Kaphajavikruti 
Madyama sara, Madyamasamhana, Prabara satmya, 
Madyama Ahara Shakti and Vyayama Shakti, 
Madyama Vaya and Pramana. The Kosto (Bowel 
Habit) was Kruro (constipated). The patient’s Asta 
vidha Prikshya (eight fold examination) as Kapha 
pitta Nadi, normal Mutra and Mala, Ama lipta 
(coated) Jivha, Kapha predominant Shabda, Sparsa 
and Drika, slightly central obesity in Akruti (general 
appearance). 
Time Line 
Time line Clinical presentation Medication 
Before Jan 2019 Asymptomatic  
Feb 2019 Heaviness, constipation No medication 
April 2019 Anorexia, indigestion, distension of 
abdomen 
modern appetizer, antacid and rapeprazole 
sodium for one months 
May 2019(D0) Anorexia, indigestion, distension of 
abdomen and came for Ayurveda 
treatment 
NAFLD diagnosed & Potala Katurohinyadi 
Kwatham - 30ml BID with equal quantity of 
water in empty stomach 
Jun 2019 (D30) No symptom Medication continued for another two month 
July 2019 No symptom and no improvement in 
USG and Fibroscan 
Medication continued for another four month 
October 2019 No symptom and improved in fibro scan Medication stopped 
Sep 2020 No symptom, Review and maintained 
health 
Normal life without medication 
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Diagnostic Assessment 
The diagnosis of NAFLD requires the 
evidence of hepatic steatosis by imaging or by 
histology. Ultrasound is very effective in diagnosis 
steatosis where more than 33% hepatocyte are 
steotic[15]. The SAF score in histology is 
encompassment of an assessment of steatosis (S), 
activity (A) and fibrosis (F) which has been 
introduced more recently to identify NASH (Non 
alcoholic Steato- hepatitis) which can progress to 
cirrhosis and end stage liver diseases[16]. The BARD 
score and NAFLD fibrosis score are simple non-
invasive tests of fibrosis assessment calculated from 
specific software. Transient elastography (TE) 
provide the Liver stiffness measurement (LSM) using 
pulse -echo ultrasound as surrogate marker of 
fibrosis[17]. 
Therapeutic Intervention  
Patolakaturohinyadi Kwatham (PKK) is a very 
famous Ayurvedic medicine in decoction form. It is 
used in the treatment of anorexia, vomiting, skin 
diseases, jaundice, viral infections and liver diseases. 
It is used in the treatment of fever and other diseases 
of Kapha and Pitta origin. It is also a potent antitoxic 
medicine used for liver detoxification. It improves 
digestion and relieves anorexia. It is a potent 
antimicrobial medicine. The main ingredients of 
Patolakaturohinyadi kwatham are, Patola 
(Trichosanthes dioica), Katurohini (Picroohiza 
kurroa), Chandana- Sandal wood (Santalum album), 
Madhusrava (Leptadenia reticulate), Guduchi 
(Tinospora cordiafolia) and Patha (Cissampelo 
spariera)[13]. The dose was 30ml Kasaya with equal 
quantity of lukewarm water twice daily in empty 
stomach preferable morning and evening. The 
treatment was given for three months initially and 
further extended for another three months. So total 
duration was done for 6 months.  
 
 
 
Follow up and outcome 
The patient was followed up in 30 days and 90 days, 
six month and observed for one year without 
medication. The patient has improved clinically and 
her haematological, biochemical and serological 
parameters gradually developed during the period of 
time (Table-2). The outcome was measured in terms 
of ultrasound and Fibro scan which showed 
improved in fibrosis score and not reappeared in one 
year of observed period. 
After 30 days of treatment, his normal 
appetite was appeared and got relieved in abdominal 
discomfort, but he gained weight one kg and his 
blood sugar and other parameter was not changed 
significantly. As the patient relieved symptoms, felt 
good he wanted to extend his treatment, therefore 
the treatment was extended for further two months. 
There was a significant change in metabolic and liver 
function tests without changes in liver architecture in 
terms of ultrasound, fibrosis scoring and fibro scan 
after three months of treatment. The treatment 
schedule was further extended to another three 
months for better outcome and observed the change 
in fibrosis of liver. After six months of medication, 
there was a significant change in metabolic and liver 
function tests as well as liver architecture in terms of 
ultrasound, fibrosis scoring and fibro scan without 
any side effect. The BARD score changed from 4 to 2 
and 0 after six month. NAFLD score <-1.455 is F0 ( no 
fibrosis). This case has mild fibrosis to no fibrosis 
after three month of therapy. The patient was kept in 
observation for further one year without medication 
and advised to practice yoga, exercise and low 
carbohydrate and fat diet to study the recurrence of 
disease. The liver architecture as well as biochemical 
profile of liver is maintained after one year also. The 
prescribed medication well tolerated as we were not 
observed adverse clinical sign and symptoms and 
there is no change in Haematological, renal and Liver 
profile.  
Table 2: Hematological, Biochemical and Serological Parameters During the Treatment and Observed 
Period 
Lab parameters D0 D30 D90 D180 After one year 
without Rx 
Weight (Kg) 75 76 73 71 66 
BMI 28.2 28.6 27.5 26.7 24.8 
FBS (mg/dl) 122 120 84 78 82 
PPBS (mg/dl) 182 178 123 118 123 
HbA1C 7.1 --- 6.4 6.2 5.8 
Serum Insulin (Fasting) µU/ml 30ml ---- 20 12 10 
Total cholesterol  139 140 120 120 122 
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Triglyceride  227 220 150 134 154 
HDL Cholesterol 38 40 40 50 68 
Haemoglobin (gm/dl) 11.7 11.6 12.4  12.6 11.8 
ESR 1st hour  06 60 50 46 50 
Platelet Count (109/L) 148 178 192 240 238 
TLC 8700 8100 8000 7800 6800 
Prothrombin Time Sec  11.4 11.4 10.2 10.2  
Sr.Bilirubin (Total) mg/dl 1.0 0.8 1.79 1.2 1.0 
Sr.Bilirubin (Direct) mg/dl 0.3 1.07 0.7 0.5 0.4 
SGOT/ ALT(IU/L) 54 56 40 40 39 
SGPT/AST(IU/L) 45 44 35 31 28 
Alkaline Phosphatase (IU/L) 138 130 136 147 108 
GGT( U/L) 64 63 40 04 05 
Total protein  6.6 7.6 7.8 7.8 7.8 
Albumin g/dl 4,2 4.2 4.6 4.6 5.2 
Urea 26 18 28 30.6 27.2 
Creatinine  0.62 0.60 0.65 0.76 0.5 
Serum ferritin (ng/ml) 180 150 154 144 155 
Ultrasound  Mild - No change  Normal  Normal 
BARD Score 04 04 02 00 00 
NAFLD fibrosis Score -1.455 -0.91 -1.86 -3.00 -3.54 
Fibroscan (Median stiffness) 12 --- 9.00 6.99 6.12 
TLC: Total Leukocyte Count 
SGOT (AST): serum glutamic- oxaloacetic 
transaminase; SGPT (ALT): serum glutamic-
oxaloacetic transaminase; GGT: Gamma- glutamyl 
transferase; ANA: anti nuclear anti body, 
DISCUSSION 
The presented patient is Kapha pitta prakruti 
and other Ayurvedic parameters of examination were 
Kapha predominant. Therefore, it is suggested that 
Ayurvedic nomenclature for Non Alcoholic Fatty 
Liver diseases (NAFLD) may be Kaphaja 
Yakruitdalludara. Patolakaturohinyadi Kwatham 
(PKK) is indicated for Kapha pittaja disorders. PKK is 
already studied in Alcoholic liver diseases, where the 
study outcome was limited to diminished the liver 
enzymes without observing the liver architecture by 
fibrosis Score, Fibro scan and ultrasound. This study 
proved that PKK can significantly reduced blood 
sugar, serum Lipids and liver enzymes within 3 
months along with reduction weight and BMI, but 
change in liver architecture required six months in 
this therapy. PKK may correct the metabolic 
dysfunction by increase Agni, digest Ama which 
helped in the correction of hyperglycaemia and 
dyslipidaemia. PKK is safe in for six months of use in 
recommended dose (30ml BID) as there was no 
adverse sign and symptom observed and no change 
in biochemical and Haematological profile of Patients. 
The patient was kept in observation for further one 
year without medication and advised to practice 
yoga, exercise and low carbohydrate and fat diet to 
study the recurrence of disease. The liver 
architecture as well as biochemical profile of liver is 
maintained after one year also. So PKK has corrected 
the metabolic error as NAFLD is said to metabolic 
associated fatty liver disease[18]. 
CONCLUSION 
PKK is safe and effective in this case of 
Kaphaja Yakrit dalludara (NAFLD). It can study 
further in large population to prove its safety and 
efficacy in meaningful way.  
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